New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2013
10:38 EDTARNAArena sinks after E.U. raises objections to weight loss drug
Arena Pharmaceuticals (ARNA) is sinking after the company reported earlier this morning in a regulatory filing that the European Medicines Agency had asked it to address issues with its anti-obesity drug, lorcaserin. The E.U. regulator raised objections to lorcaserin based on previously identified risk factors for patients taking the drug, including hypertension, cardiovascular disease, type 2 diabetes, and sleep apnea, Arena reported. The company will have to address the issues before the drug can be approved by the E.U., Arena stated, adding that the regulator is still expected to make a decision on the drug in the first half of 2013. In a note to investors earlier today, Piper Jaffray analyst Edward Tenthoff wrote that the E.U. regulator wants Arena to justify the drug's overall risk/reward benefit. Arena doesn't have a partner for the drug in Europe yet, and will probably not be able to obtain one until it clears up the issues raised by the regulator, the analyst added. Tenthoff reiterated an $11 price target and Overweight rating on the shares, which dropped 64c, or 6.55%, to $9.12 in mid-morning trading.
News For ARNA From The Last 14 Days
Check below for free stories on ARNA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
07:43 EDTARNABofA/Merrill to hold a conference
Subscribe for More Information
September 16, 2014
09:59 EDTARNAArena to need longer studies of 'Bel-phen' combo to judge safety, TheStreet says
Subscribe for More Information
September 11, 2014
12:42 EDTARNAOrexigen falls after FDA requires warnings on Contrave label
Subscribe for More Information
10:59 EDTARNAArena competition picks up after Contrave approval, says Piper Jaffray
Subscribe for More Information
08:01 EDTARNAOrexigen Contrave could have stronger launch than peers, says Wells Fargo
After the FDA approved Orexigen's (OREX) Contrave as a treatment option for chronic weight management, Wells Fargo does not believe the label included any significant surprises. The firm thinks multiple factors increase the chances that Contrave's launch will be stronger than two other weight loss drugs that were launched in recent years by VIVUS and Arena Pharmaceuticals (ARNA). The firm keeps an Outperform rating on Orexigen.
September 9, 2014
12:46 EDTARNANovo Nordisk weight loss drug helped people get thinner, Bloomberg reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use